La Stratégie et plan d’action sur la promotion de la santé dans le contexte des objectifs de développement
durable 2019-2030 cherche à renouveler la promotion de la santé grâce à des interventions de nature sociale,
politique et technique, en agissant sur les déterminants sociaux de la s...anté, à savoir les conditions dans
lesquelles les personnes naissent, grandissent, vivent, travaillent et vieillissent (1). Ils visent à améliorer la
santé et à réduire les iniquités en matière de santé dans le cadre du Programme de développement durable à
l’horizon 2030
more
This manual and its Excel tool are under revision. The revised edition will be published soon.
A corruption event in 2009 led to changes in how donors supported the Zambian health system. Donor funding was withdrawn from the district basket mechanism, originally designed to pool donor and government financing for primary care. The withdrawal of these funds from the pooled financing mechanism ...raised questions from Government and donors regarding the impact on primary care financing during this period of aid volatility.
more
: Development assistance for health (DAH) is one of the most important means for Japan to promote
diplomacy with developing countries and contribute to the international community. This study, for the first time,
estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarified its... flows, including source, aid
type, channel, target region, and target health focus area
more
Development assistance for health (DAH) is an important part of financing healthcare in low- and middle-income countries. We estimated the gross disbursement of DAH of the 29 Development Assistance Committee (DAC) member countries of the Organisation for Economic Co-operation and Development (OECD) ...for 2011–2019; and clarified its flows, including aid type,
channel, target region, and target health focus area. Data from the OECD iLibrary were used. The DAH definition was based on the OECD sector classification. For core funding to non-healthspecific multilateral agencies, we estimated DAH and its flows based on the OECD methodology for
calculating imputed multilateral official development assistance (ODA).
more
2nd edition. Essential guideline for humanitarian assistance
A guide to promote health systems strengthening to achieve universal health coverage.
This publication is part of WHO 75th anniversary and aims to capture key successes in public health globally and in Namibia. It includes contributory messages from the Head of State, Prime Minister and the Minister of Health and Social Services.
Moving from accelerated burden reduction to malaria elimination in Zambia
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Teymur Noori, with technical support from Andrew J. Amato-Gauci, Anastasia Pharris, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Teymur Noori. Report review was provided by Andrew J. Amato-Gauci, Anastasia Pharris, Annabelle Gourlay, Amanda Mocroft, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
Recommendations on action and research for:
a) preventing early pregnancy
b) preventing poor reproductive outcomes
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more